Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales Analysis End-User The global blood transfusion market will witness a robust CAGR of 6%, valued at $6.7 billion in 2021, expected to appreciate and reach $11.31 billion by 2030, confirms Strategic Market Research. Transferring blood or blood components intravenously into the body’s circulation system is known as blood transfusion. The primary use of Transfusions is to replenish lost blood components in a variety of medical situations. Medical equipment used in collecting, processing, separating, and storing blood and blood products is blood transfusion devices. Transfusions are used to treat anaemia, sickle cell disease, and bleeding disorders like hemophilia, cancer, etc. The Most Common Reasons for Transfusion: Cardiovascular operations, C-section procedures, trauma, and accident injuries are the most common surgeries requiring blood transfusion. According to the estimations from the National Institutes of Health and the National Heart, Lung, and Blood Institute, blood transfusions are pretty prevalent in the United States, with over 5 million Americans needing a blood transfusion each year. The vast majority of operations are for cardiovascular procedures. Blood transfusions are not a cure for aplastic anemia, but they can help control bleeding and relieve the symptoms by providing extra blood cells. Normal hemoglobin levels are 120-160 grams per liter, depending on age and gender. However, 70 g / L is usually a safe value. Recent Studies have Shown that: Many patients with hemoglobin levels above 70 or 80 g / L may not require blood transfusions. One blood units are usually as good as two units of blood transfusion and can be even safer. Phlebotomy, which is usually done at the blood banks, is similar to a regular blood donation. In some cases, blood donated by individuals with hemochromatosis is used by people who need a blood transfusion. Common types of blood transfusions include red blood cell transfusion, platelet transfusion, and plasma transfusions. Patients with iron deficiency or anemia who do not have enough red blood cells in their bodies may receive red blood cell transfusions. This type of blood transfusion for anemia patients increases the content of hemoglobin and iron levels. All the blood transfusions are tested to detect specific diseases such as hepatitis B and C and the human immunodeficiency virus (HIV). Reducing exposure to donors can reduce the risk of transmitting the infection and developing alloimmunity and other transfusion-related complications. Alloimmunization refers to the most common immune response to foreign antigens of others during pregnancy or after a blood transfusion. Impact of Covid-19 The sudden outbreak of COVID-19 caused strict lockdown measures in various countries, causing difficulties in the market. COVID-19 can have three significant effects on the global economy: directly impacting production and demand, causing supply chain and market disruption, and having a financial impact on businesses and financial markets, thereby affecting the Blood Transfusion Market. Across the globe, the covid-19 pandemic had caused substantial obstacles to the healthcare system. Patients postponed their visits because of a quick increase of covid-19 instances across regions, thus, severely impacting the growth of the market. In addition, supply chain problems caused by the shutdown of the entire system hampered the market’s growth rate. Also, because of the fear of coronavirus infection, people only left their homes for needed services, which slowed market expansion for a long time. Moreover, the Covid-19 pandemic has caused havoc in the health industry. Consequently, the market faced various challenges in the demand and supply of Blood banks and Transfusion Services, which negatively affected the Blood Transfusion Diagnostics Market and Blood Transfusion Devices Market. Market Dynamics - The Rising Number of Surgical Operations, Technological Advancements, and Increase in the Number of Accidents are some of the Major Components Driving the Market Factors like the rising number of surgical operations, increase in accidents, trauma cases, and blood diseases are the primary causes driving the market forward. In addition, as a result of natural disasters and widespread causalities, the need for blood transfusions is rising over the world. Anemia, leukopenia, erythrocytosis, leukocytosis, and thrombocytosis are all on the rise, helping to drive the market forward. Moreover, Diabetes incidence is predicted to rise, and new product introductions will likely propel the market forward. Moreover, the growing usage of blood transfusion in the pediatric, adult and elderly populations is driving the global market. Referring to World Health Organisation, around 1.3 million people die yearly due to road traffic crashes. By 2030, a target of reducing the number of deaths and injuries from road traffic crashes by half is planned by The United Nations General Assembly. Most countries cost 3% of their gross domestic product due to road traffic crashes. More than 1/2 of all road traffic deaths are heavy road users: pedestrians, cyclists, and motorcyclists. Moreover, 93% of the world’s fatalities on the roads arise in low- and middle-profit nations, although those nations have about 60% of the world’s vehicles. Road site visitor accidents are the main reason for the death of youngsters and teens elderly 5-29 years; WHO’s data proves that increasing the number of traumatic injuries will drive the Market. Bloodborne Infections due to Blood Transfusion System going to Hamper the Market Growth: According to the World Health Organization, most infants with thalassemia are born in low-income nations, where blood transfusion is challenging to come by or is only provided to a small fraction of the population. However, adverse effects of using a Blood Transfusion system lead to fever, virus and infection illness, allergic responses, and bloodborne diseases, which are expected to stifle the expansion of this market. Technological Advancement in the Field of Blood Transfusion to Offer New Opportunities in the Market: Due to the increase in technical developments, the market for blood transfusions is advancing rapidly. The use of stem cell technologies to create lab-grown blood cells for human transfusion is one of the most innovative research methods. Additionally, increased consumer awareness and increasing acceptance of blood transfusion in emerging nations are expected to generate profitable prospects for the market participants during the projected period. Market Analysis Of Different Segments Covered in the Report Market Breakup by End-User Hospitals Ambulatory Surgical Centers Blood Bank Others Regional Coverage Analysis North America The U.S. Canada Mexico Europe Germany France UK Italy Spain Rest of Europe Asia-Pacific Japan China India Australia South Korea Thailand Rest of Asia-Pacific LAMIA Brazil Turkey Saudi Arabia Republic of South Africa Rest of LAMEA North America is observed to have the most significant market share in 2020, and as per the estimations, the market will increase significantly throughout the forecasted period. An increasing number of surgical operations and an increasing geriatric population will drive the regional market’s growth. Moreover, because of advancements in healthcare infrastructures of the emerging nations, the market in Asia-Pacific is expected to grow at a rapid rate. In 2020, the ‘hospital’ market segment had the most significant market share, accounting for more than 30% of the whole market. The ' hospitals ' are due to the increasing occurrences of trauma and accident cases. Moreover, during the forecasted period, the blood bank segment is expected to increase exponentially. Blood Transfusion Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 6.7 Billion The revenue forecast in 2030 USD 11.31 Billion Growth rate CAGR of approximately 6.0% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation Market Breakup by End-User, Market Breakup by Geography, Based on End-User, Based on Regions. Market Breakup by End-User Hospitals, Blood Bank, Ambulatory Surgical Centers, and Others. Market Breakup by Geography North America, Europe, Asia Pacific, LAMIA. Country Scope U.S, Canada, France, Germany, U.K, China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles B. Braun Melsungen AG, Becton Dickinson, Haemonetics Corporation, Terumo Corporation, Kaneka Corporation, Grifols SA, Macopharma SA, Fresenius Kabi, Immucor Inc. Pricing and purchase options Avail customized purchase options to meet your exact research needs. Blood Transfusion Market Competitive Landscape Analysis The key players in this market are as follows: B. Braun Melsungen AG Becton Dickinson Haemonetics Corporation Terumo Corporation Kaneka Corporation Grifols SA Macopharma SA Fresenius Kabi Immucor Inc. Recent Developments On April 2021, Terumo Blood and Cell Technologies and CSL Plasma teamed up to create a new plasma collection platform. On January 2020, Fresenius Kabi invested €30 million in the Dominican Republic to expand its transfusion and apheresis disposables factory. On April 2019, Platelet Quality Control Media was introduced by B.D. to Help Reduce the Incidence of Sepsis in Platelet Transfusion Patients, Frequently Asked Question About This Report How big will the Blood Transfusion Market be? The global blood transfusion market size was $6.7 Billion in 2021 and is predicted to reach $11.31 Bn by 2030, at a CAGR of 6% throughout the forecasted period of 2021-2030. What is the total blood transfusion market size? In 2021, the valuation of the Blood transfusion market was USD 6.7 billion. What is the blood transfusion market growth? The market is witnessing a market growth of 6 % during the forecasted period. Who are the leading players in the market? Key players of this market are B. Braun Melsungen AG, Becton Dickinson, Haemonetics Corporation, Terumo Corporation, Kaneka Corporation, Grifols SA, Macopharma SA, Fresenius Kabi, Immucor Inc. What are the various factors driving the market? Increasing blood infections during transfusion, rising number of surgical procedures and rising adoption of blood transfusion filters in developing economies drive the overall market’s growth. In which region do growth rates have the highest levels in the market? Asia-pacific is expected to have the highest growth rate due to the high population and fast economic growth. Which region has the largest share in the market? North America has asignificant market share in the market. Sources https://givingblood.org/about-blood/blood-facts.aspx https://www.who.int/news-room/fact-sheets/detail/road-traffic-injuries https://www.terumo.com/newsrelease/detail/20210419/604 https://www.fresenius-kabi.com/news/inauguration-transfusion-and-apheresis-disposables-plant Chapter 1. Introduction 1.1 Study Objectives 1.2 Market Definition Table 1 Inclusions and Exclusions 1.3 Study Scope 1.3.1 Markets Covered Figure 01: Segmentation 1.3.2 Geographic Scope Figure 02: Geography covered 1.3.3 Years Considered 1.4 Stakeholders Chapter 2. Research Methodology 2.1 Data Procurement 2.2 Paid Database 2.2.1 Secondary Data 2.2.1.1 Key Secondary sources 2.2.2 Primary Data 2.2.2.1 Primary sources 2.2.2.2 Key industry insights 2.2.2.3 Primary interviews with experts 2.2.2.4 Key primary respondent list 2.3 Market Size Estimation 2.4 Bottom-Up and Top-Down Approaches 2.4.1 Bottom-Up Approach 2.4.1.1 Approach for arriving at market size by bottom-up analysis Figure 03: : Bottom-Up Approach 2.4.2 Top-Down Approach 2.4.2.1 Approach for Capturing Market Size by Top-Down Analysis Figure 04: : Top-Down Approach 2.5 Market Breakdown and Data Triangulation Figure 05: Data Triangulation 2.6 Research Methodology 2.7 Risk Assessment Table 2: Risk Assessment Chapter 3. Executive Summary 3.1 : Post-Covid-19 Figure 06: Impact of Covid-19 on 3.1.1 Actual Scenario Figure 07: Realistic Scenario: , 2021–2030 (USD Million) 3.1.2 Pessimistic Scenario Figure 08: Pessimistic Scenario: , 2021–2030 (USD Million) 3.1.3 Optimistic Scenario Figure 09: Optimistic Scenario: , 2021–2030(USD Million) 3.1.4 Market Summary Figure 10: North America to Account for Largest Share of Global In 2021 Chapter 4. Market Definitions 4.1 Market Segmentation Figure 11: Segmentation Chapter 5. Industry Outlook 5.1 Market Snapshot 5.2 Global Blood Transfusion Market 5.2.1 Global , 2021 – 2030 (USD Million) 5.3 Regional Segment Analysis 5.3.1 Global , by region, 2021 - 2030 (USD Million) 5.4 Type Segment Analysis 5.4.1 Global , by Type, 2021 - 2030 (USD Million) 5.5 End-User Segment Analysis 5.5.1 Global , By End-User, 2021 - 2030 (USD Million) 5.6 Value Chain Analysis 5.7 Market Variable Analysis 5.7.1 Market Drivers Analysis 5.7.2 Market Restraints Analysis 5.8 Business Environment Analysis Tool 5.8.1 PEST analysis 5.8.2 Porter’s analysis 5.9 Penetration & Growth Prospect Mapping Chapter 6. Market Overview 6.1 Introduction 6.2 Market Dynamics Figure 12 : Drivers, Restraints, Opportunities, and Challenges 6.2.1 Drivers Figure 13 Drivers and Their Impact 6.2.2 Restraints Figure 14 Restraints and Their Impact 6.2.3 Opportunities Figure 15 Opportunities and Their Impact 6.2.4 Challenges Figure 16 Challenges and Their Impact 6.3 Impact of Covid-19 on 6.4 Value Chain Analysis Figure 17 Value Chain Analysis: 6.5 Ecosystem Figure 18 : Ecosystem Table 3 : Ecosystem Figure 19 Revenue Shift in 6.6 Patent Analysis Table 4 Number of Patents Registered in in USA in Last 9 Years Figure 20 Top 9 Companies with Highest No. of Patents in Last 9 Years Figure 21 No of Patents Granted Per Year, 2019–2021 Table 5 List of Global Patents in 6.8 Tariff Analysis 6.9 Case Study Analysis 6.10 Porter’s Five Forces Analysis Table 6 : Porter’s Five Forces Analysis, 2021 6.10.1 Threat of New Entrants 6.10.2 Threat of Substitutes 6.10.3 Bargaining Power of Buyers 6.10.4 Bargaining Power of Suppliers 6.10.5 Degree of Competition 6.11 Technology Analysis 6.11.1 Trends in Technology (2014-2021) 6.11.2 Trends in Technology (2021 - 2030) Table 7 Key Regulations: 6.12 Pricing Analysis 6.12.1 Average Price Trend Analysis (By region, By Countries) Chapter 7. Competitive & Vendor Landscape 7.1 Company Market Share Analysis Table 8: Key Players market share Figure 22: Key players market share of companies 7.2 Manufacturers Blood transfusion Manufacturing Sites, Area Served, End-User 7.3 Competitive Situation and Trends 7.4 Manufacturers Mergers & Acquisitions, Expansion Plans Chapter 8. Global : End-User Segment Analysis 8.1 Introduction 8.2 Sales Volume & Revenue Analysis (2021 - 2030) Table 9: , By End-User, 2021–2030 (USD Million) Figure 23: , By End-User, 2021–2030 (USD Million) 8.3 Hospitals 8.3.1 Hospitals market, 2021 - 2030 (USD Million) Figure 24: Hospitals market, 2021 - 2030 (USD Million) 8.4 Blood Bank 8.4.1 Blood Bank, 2021 - 2030 (USD Million) Figure 25: Blood Bank, 2021 - 2030 (USD Million) 8.5 Ambulatory Surgical Centers 8.5.1 Ambulatory Surgical Centres market, 2021 - 2030 (USD Million) Figure 26: Ambulatory Surgical Centres market, 2021 - 2030 (USD Million) 8.6 Others 8.6.1 Others market, 2021 - 2030 (USD Million) Figure 27: Others market, 2021 - 2030 (USD Million) Chapter 9. Global : Regional Outlook 9.1 North America Figure 28: North America , By Revenue Forecast (2021 - 2030) 19.1.1 North America , By country, 2021 - 2030 (USD Million) Table 10: North America , by Country, 2021 - 2030 Figure 29: North America 9.1.2 North America , By End-User, 2021 - 2030 (USD Million) Table 11: North America , By End-User, 2021 - 2030 (USD Million) Figure 30: North America , By End-User, 2021 - 2030 (USD Million) 9.1.3 U.S. 10.1.3.1 U.S. , by End-User, 2021 - 2030 (USD Million) Figure 31: U.S. , by End-User, 2021 - 2030 (USD Million) 9.1.4 Canada 10.1.4.1 Canada , By End-User, 2021 - 2030 (USD Million) Figure 32: Canada , By End-User, 2021 - 2030 (USD Million) Figure 33: Canada , by End-User, 2021 - 2030 (USD Million) Figure 34: Canada , by End-User, 2021 - 2030 (USD Million) 9.2 Europe Figure 35: Europe , By Revenue Forecast (2021 - 2030) 9.2.1 Europe , by country, 2021 - 2030 (USD Million) Table 12: Europe , by country, 2021 - 2030 (USD Million) Figure 36: Europe , by country, 2021 - 2030 (USD Million) 9.2.2 Europe , by End-User, 2021 - 2030 (USD Million) Table 13: Europe , by End-User, 2021 - 2030 (USD Million) Figure 37: Europe , by End-User, 2021 - 2030 (USD Million) 9.2.3 U.K. 9.2.3.1 U.K. , by End-User, 2021 - 2030 (USD Million) Figure 38: U.K. , by End-User, 2021 - 2030 (USD Million) 9.2.4 Germany 9.2.4.1 Germany , by End-User, 2021 - 2030 (USD Million) Figure 39: Germany , by End-User, 2021 - 2030 (USD Million) 9.2.5 France 9.2.5.1 France , by End-User, 2021 - 2030 (USD Million) Figure 40: France , by End-User, 2021 - 2030 (USD Million) 9.2.6 Rest of Europe 9.2.6.1 Rest of Europe , by End-User, 2021 - 2030 (USD Million) Figure 41: Rest of Europe , by End-User, 2021 - 2030 (USD Million) 9.3 Asia Pacific Figure 42: Asia Pacific , By Revenue Forecast (2021 - 2030) 9.3.1 Asia Pacific , by country, 2021 - 2030 (USD Million) Table 14: Asia Pacific , by country, 2021 - 2030 (USD Million) Figure 43: Asia Pacific , by country, 2021 - 2030 (USD Million) 9.3.2 Asia Pacific , by End-User, 2021 - 2030 (USD Million) Table 15: Asia Pacific , by End-User, 2021 - 2030 (USD Million) Figure 44: Asia Pacific , by End-User, 2021 - 2030 (USD Million) 9.3.3 China 9.3.3.1 China , by End-User, 2021 - 2030 (USD Million) Figure 45: China , by End-User, 2021 - 2030 (USD Million) 9.3.4 India 9.3.4.1 India , by End-User, 2021 - 2030 (USD Million) Figure 46: India , by End-User, 2021 - 2030 (USD Million) 9.3.5 Japan 9.3.5.1 Japan , by Type, 2021 - 2030 (USD Million) Figure 47: Japan , by Type, 2021 - 2030 (USD Million) 9.3.5.2 Japan , by End-User, 2021 - 2030 (USD Million) Figure 48: Japan , by End-User, 2021 - 2030 (USD Million) 9.3.6 South Korea 9.3.6.1 South Korea , by End-User, 2021 - 2030 (USD Million) Figure 49: South Korea , by End-User, 2021 - 2030 (USD Million) 9.3.7 Rest of APAC 9.3.7.1 Rest of APAC , by End-User, 2021 - 2030 (USD Million) Figure 50: Rest of APAC , by End-User, 2021 - 2030 (USD Million) 9.4 Latin America Figure 51: Latin America , By Revenue Forecast (2021 - 2030) 9.4.1 Latin America , by country, 2021 - 2030 (USD Million) Table 16: Latin America , by country, 2021 - 2030 (USD Million) Figure 52: Latin America , by country, 2021 - 2030 (USD Million) 9.4.2 Latin America , by End-User, 2021 - 2030 (USD Million) Table 17: Latin America , by End-User, 2021 - 2030 (USD Million) Figure 53: Latin America , by End-User, 2021 - 2030 (USD Million) 9.4.3 Brazil 9.4.3.1 Brazil , by End-User, 2021 - 2030 (USD Million) Figure 54: Brazil , by End-User, 2021 - 2030 (USD Million) 9.4.4 Mexico 9.4.4.1 Mexico , by End-User, 2021 - 2030 (USD Million) Figure 55: Mexico , by End-User, 2021 - 2030 (USD Million) 9.4.5 Rest of the Latin America 9.4.5.1 Rest of the Latin America , by End-User, 2021 - 2030 (USD Million) Figure 56: Rest of the Latin America , by End-User, 2021 - 2030 (USD Million) 9.5 MEA Figure 57: MEA , By Revenue Forecast (2021 - 2030) 9.5.1 MEA , by End-User, 2021 - 2030 (USD Million) Figure 58: MEA , by End-User, 2021 - 2030 (USD Million) Chapter 10. Competitive Landscape 10.1 B. Braun Melsungen AG. 10.1.1 Company overview 10.1.2 Financial performance 10.1.3 Product Portfolio Analysis 10.1.4 Business Strategy & Recent Development 10.2 Becton Dickinson. 10.2.1 Company overview 10.2.2 Financial performance 10.2.3 Product Portfolio Analysis 10.2.4 Business Strategy & Recent Development 10.3 Haemonetics Corporation. 10.3.1 Company overview 10.3.2 Financial performance 10.3.3 Product Portfolio Analysis 10.3.4 Business Strategy & Recent Development 10.4 Terumo Corporation. 10.4.1 Company overview 10.4.2 Financial performance 10.4.3 Product Portfolio Analysis 10.4.4 Business Strategy & Recent Development 10.5 Kaneka Corporation. 10.5.1 Company overview 10.5.2 Financial performance 10.5.3 Product Portfolio Analysis 10.5.4 Business Strategy & Recent Development 10.6 Grifols SA. 10.6.1 Company overview 10.6.2 Financial performance 10.6.3 Product Portfolio Analysis 10.6.4 Business Strategy & Recent Development 10.7 Macopharma SA. 10.7.1 Company overview 10.7.2 Financial performance 10.7.3 Product Portfolio Analysis 10.7.4 Business Strategy & Recent Development 10.8 Fresenius Kabi. 10.8.1 Company overview 10.8.2 Financial performance 10.8.3 Product Portfolio Analysis 10.8.4 Business Strategy & Recent Development 10.9 Immucor Inc. 10.9.1 Company overview 10.9.2 Financial performance 10.9.3 Product Portfolio Analysis 10.9.4 Business Strategy & Recent Development